Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of ProQuad® rHA in Infants (V221-037)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subject of either gender,~* Age from 12 to 22 months,~* Negative clinical history of infection with measles, mumps, rubella, varicella or zoster,~* Informed consent form signed by the parent(s) or by legal representative~* Parent(s) or legal representative able to attend all schedule visits with the subject and to understand and comply with the study procedures~Exclusion Criteria:~* Recent (≤ 3 days) history of febrile illness~* Prior receipt of measles, mumps, rubella and/or varicella vaccination, either alone or in any combination~* Recent (≤ 30 days) exposure to measles, mumps, rubella, varicella or zoster~* Prior known sensitivity/allergy to any component of the vaccine~* Severe chronic disease,~* Blood dyscrasias, leukaemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic system~* Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection~* Humoral or cellular immunodeficiency,~* Current immunosuppressive therapy~* Family history of congenital or hereditary immunodeficiency~* Hereditary problems of fructose intolerance~* Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition,~* Known active tuberculosis~* Recent (≤ 2 days) tuberculin test or scheduled tuberculin test through Visit 3~* Receipt of immunoglobulins or blood-derived products in the past 150 days~* Receipt of an inactivated vaccine in the past 14 days~* Receipt of a live vaccine in the past 28 days~* Any medical condition which, in the opinion of the investigator, might interfere with the evaluation of study objectives~* Participation in another clinical study in the past 30 days

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 22 Months
- Healthy Volunteers: t

Study Arms:
- ProQuad® (Type: EXPERIMENTAL): Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.

Based on this trial design, predict the completion outcome and termination type (if applicable).